Late Thursday, Cybin Announced Publication of Sponsored Feasibility Study Validating Kernel's Flow1 Neuroimaging Technology Measuring Psychedelic Effects On The Brain
Portfolio Pulse from Benzinga Newsdesk
Cybin has announced the publication of a sponsored feasibility study validating Kernel's Flow1 neuroimaging technology for measuring psychedelic effects on the brain.
July 21, 2023 | 8:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The publication of a sponsored feasibility study by Cybin validates Kernel's Flow1 neuroimaging technology, potentially boosting Cybin's credibility in the field of psychedelic research.
The validation of Kernel's Flow1 technology through a study sponsored by Cybin could enhance Cybin's reputation in the field of psychedelic research. This could potentially attract more investors, leading to a positive impact on the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100